BRPI0923182A2 - 6-cyclamino-2,3-di-pyridinyl-imidazo [1,2-b] pyridazine derivatives, their preparation and their preparation and their therapeutic application - Google Patents

6-cyclamino-2,3-di-pyridinyl-imidazo [1,2-b] pyridazine derivatives, their preparation and their preparation and their therapeutic application

Info

Publication number
BRPI0923182A2
BRPI0923182A2 BRPI0923182A BRPI0923182A BRPI0923182A2 BR PI0923182 A2 BRPI0923182 A2 BR PI0923182A2 BR PI0923182 A BRPI0923182 A BR PI0923182A BR PI0923182 A BRPI0923182 A BR PI0923182A BR PI0923182 A2 BRPI0923182 A2 BR PI0923182A2
Authority
BR
Brazil
Prior art keywords
preparation
cyclamino
imidazo
pyridinyl
therapeutic application
Prior art date
Application number
BRPI0923182A
Other languages
Portuguese (pt)
Inventor
Puech Frédéric
Barrague Matthieu
Sevrin Mireille
George Pascal
A Metz William
Chiang Yulin
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of BRPI0923182A2 publication Critical patent/BRPI0923182A2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Epidemiology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BRPI0923182A 2008-12-19 2009-12-17 6-cyclamino-2,3-di-pyridinyl-imidazo [1,2-b] pyridazine derivatives, their preparation and their preparation and their therapeutic application BRPI0923182A2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0807257A FR2940284B1 (en) 2008-12-19 2008-12-19 6-CYCLOAMINO-2,3-DI-PYRIDINYL-IMIDAZO-1,2-B-PYRIDAZINE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE
US13965208P 2008-12-22 2008-12-22
PCT/FR2009/052594 WO2010070238A1 (en) 2008-12-19 2009-12-17 Derivatives of 6-cycloamino-2,3-di-pyridinyl-imidazo[1,2-b]-pyridazine, preparation and therapeutic application thereof

Publications (1)

Publication Number Publication Date
BRPI0923182A2 true BRPI0923182A2 (en) 2019-09-24

Family

ID=40848284

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0923182A BRPI0923182A2 (en) 2008-12-19 2009-12-17 6-cyclamino-2,3-di-pyridinyl-imidazo [1,2-b] pyridazine derivatives, their preparation and their preparation and their therapeutic application

Country Status (12)

Country Link
EP (1) EP2385946A1 (en)
JP (1) JP2012512853A (en)
KR (1) KR20110095964A (en)
CN (1) CN102325773A (en)
AR (1) AR074685A1 (en)
AU (1) AU2009329427A1 (en)
BR (1) BRPI0923182A2 (en)
CA (1) CA2747365A1 (en)
FR (1) FR2940284B1 (en)
SG (1) SG172181A1 (en)
TW (1) TW201028420A (en)
WO (1) WO2010070238A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2935272B1 (en) * 2012-12-21 2017-02-22 Bristol-Myers Squibb Company Pyrazole substituted imidazopyrazines as casein kinase 1 d/e inhibitors
JP6267231B2 (en) 2012-12-21 2018-01-24 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Novel substituted imidazoles as casein kinase 1δ / ε inhibitors
RU2016132574A (en) * 2014-01-09 2018-02-12 Интра-Селлулар Терапиз, Инк. ORGANIC COMPOUNDS
US9956220B2 (en) 2014-06-19 2018-05-01 Bristol-Myers Squibb Company Imidazo-pyridazine derivatives as casein kinase 1 δ/ϵ inhibitors
CA3128946A1 (en) 2019-02-07 2020-08-13 Bayer Aktiengesellschaft 3-amino-2-[2-(acylamino)pyridin-4-yl]-1,5,6,7-tetrahydro-4h-pyrrolo[3,2-c]pyridin-4-one as csnk1 inhibitors
WO2022023341A1 (en) 2020-07-29 2022-02-03 Bayer Aktiengesellschaft Substituted 1 h-pyrrolo[3,2-b]pyridin compounds and methods of use thereof
WO2023064857A1 (en) 2021-10-14 2023-04-20 Incyte Corporation Quinoline compounds as inhibitors of kras
EP4469457A4 (en) * 2022-01-27 2026-01-21 Broad Inst Inc SUBSTITUTED HETEROCYCLICAL CSNK1 HIBITORS

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989001333A1 (en) * 1987-08-07 1989-02-23 The Australian National University IMIDAZO[1,2-b]PYRIDAZINES
AR041292A1 (en) * 2002-09-19 2005-05-11 Schering Corp PIRAZOLOPIRIDINAS AS CYCLINE DEPENDENT KINASE INHIBITORS
WO2004058769A2 (en) * 2002-12-18 2004-07-15 Vertex Pharmaceuticals Incorporated Triazolopyridazines as protein kinases inhibitors
DE602004020685D1 (en) 2003-12-11 2009-05-28 Aventis Pharma Inc SUBSTITUTED 1H-PYRROLO-3,2-B, 3,2-C AND 2,3-CYPYRIDINE-2-CARBOXYLIC AMIDE AND RELATED ANALOGS AS INHIBITORS OF CASEIN KINASE-I-EPSILON
WO2005107760A1 (en) * 2004-04-30 2005-11-17 Irm Llc Compounds and compositions as inducers of keratinocyte differentiation
US20080167314A1 (en) * 2004-12-28 2008-07-10 Osamu Uchikawa Condensed Imidazole Compound And Use Thereof
GB0515026D0 (en) * 2005-07-21 2005-08-31 Novartis Ag Organic compounds
DE102005042742A1 (en) * 2005-09-02 2007-03-08 Schering Ag Substituted imidazo [1,2b] pyridazines as kinase inhibitors, their production and use as pharmaceuticals
FR2918061B1 (en) * 2007-06-28 2010-10-22 Sanofi Aventis 6-CYCLOAMINO-3- (PYRIDIN-4-YL) IMIDAZO-1,2-B1-PYRIDAZINE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE.
FR2918986B1 (en) * 2007-07-19 2009-09-04 Sanofi Aventis Sa 6-CYCLOAMINO-3- (PYRIDAZIN-4-YL) IMIDAZO [1,2-B] -PYRIDAZINE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE

Also Published As

Publication number Publication date
CN102325773A (en) 2012-01-18
JP2012512853A (en) 2012-06-07
EP2385946A1 (en) 2011-11-16
TW201028420A (en) 2010-08-01
SG172181A1 (en) 2011-07-28
AU2009329427A1 (en) 2011-07-07
FR2940284A1 (en) 2010-06-25
AR074685A1 (en) 2011-02-02
WO2010070238A1 (en) 2010-06-24
CA2747365A1 (en) 2010-06-24
KR20110095964A (en) 2011-08-25
FR2940284B1 (en) 2011-02-18

Similar Documents

Publication Publication Date Title
BRPI0910309A2 (en) poly-substituted 2-arylphenyl-imidazo [1,2-a] pyridines derivatives, their preparation and their therapeutic application
BRPI1012857A2 (en) cyclopenta [c] pyrrol-2-carboxylate derivatives, their preparation and their therapeutic application
BRPI0908999A2 (en) Poly-substituted 2-aryl-6-imidazo [1,2-a] pyridines derivatives, their preparation and their therapeutic application
BRPI0907381A2 (en) Azabicyclic carboxamide derivatives, their preparation and their therapeutic application.
BRPI0810412A2 (en) PYRIDINE-CARBOXAMIDES AND Triazole PYRIMIDINE-CARBOXAMIDES DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION
BRPI0810440A2 (en) Triazolopyridine-CARBOXAMIDES AND Triazolopyrimidine-CARBOXAMIDES DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION IN THERAPEUTIC
BRPI0907439A2 (en) Azabicyclic carboxamides derivative, their preparation and their therapeutic application
IL204663A0 (en) Nicotinamide derivatives, preparastion thereof and therapeutic use thereof
SI2069342T1 (en) 2-ARYL-6-PHENYLIMIDAZO?á1,2-A?åPYRIDINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF
BRPI0906567A2 (en) Tetrahydroquinoxaline urea derivatives, their preparation and their therapeutic application
IL210514A0 (en) Pyridino-pyridinone derivatives, preparation thereof, and therapeutic use thereof
BRPI0923182A2 (en) 6-cyclamino-2,3-di-pyridinyl-imidazo [1,2-b] pyridazine derivatives, their preparation and their preparation and their therapeutic application
IL204814A0 (en) Quinazolinedione derivatives, preparation thereof and therapeutic uses thereof
BRPI0810430A2 (en) PYRIDINE Triazole derivatives - CARBOXAMIDES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION
BRPI1015943A2 (en) 1,2,3,4-tetrahydro-pyrimido [1,2-a] pyrimidin-6-one derivatives, their preparation and their pharmaceutical use.
BR112012000104A2 (en) pyrazole derivatives, their preparation and their application in therapeutic
BRPI0907578A2 (en) 3-aminoalkyl-1,3-dihydro-2h-indol-2-one derivatives, their preparation and their therapeutic application
BRPI0923875A2 (en) 2-Pyridin-2-yl-pyrazol-3 (2h) -one derivatives, their preparation and their therapeutic application.
BRPI0821992A2 (en) N-Heterocyclic-imidazo [1,2-a] pyridine-2-carboxamide s derivatives, their preparation and their therapeutic application
BRPI0821426A2 (en) Compounds of n-phenylimidazo [1,2-a] pyridine-2-carboxamides, their preparation and their therapeutic application.
BRPI0822054A2 (en) Azetidine derivatives, their preparation and their therapeutic application
BRPI0821458A2 (en) 6-Heterocyclic-imidazo [1,2-a] pyrroin-2-carboxamide s derivative, their preparation and their application in therapeutics
BRPI0806969A2 (en) AZABICYCLALCANE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION
BRPI0821674A2 (en) N-phenyl-imidazo [1,2-a] pyridine-2-carboxamides derivatives, their preparation and their therapeutic application
BRPI0814756A2 (en) tricyclic n-heteroaryl carboxamides derivatives, their preparation and their therapeutic application

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.